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Abstract 
Epigenetic processes play a key role in the central nervous system and altered levels of 5-methylcytosine 
have been associated with a number of neurological phenotypes, including Alzheimer’s disease (AD).  
Recently three additional cytosine modifications have been identified (5-hydroxymethylcytosine, 5-
formylcytosine and 5-carboxylcytosine), which are thought to be intermediate steps in the demethylation of 5-
methylcytosine to unmodified cytosine. Little is known about the frequency of these modifications in the 
human brain during health or disease. In this study we used immunohistochemistry to confirm the presence 
of each modification in human brain and investigate their cross-tissue abundance in Alzheimer’s disease 
patients and elderly control samples. We identify a significant AD-associated decrease in global 5-
hydroxymethylcytosine in entorhinal cortex and cerebellum, and differences in 5-formylcytosine levels 
between brain regions. Our study further implicates a role for epigenetic alterations in AD.  
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1. Introduction 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease affecting >5.4 million adults in the US and 
contributing significantly to the global burden of disease (Thies and Bleiler, 2011). Given the high heritability 
estimates for AD (Gatz, et al., 2006), considerable effort has focussed on understanding the role of genetic 
variation in disease etiology, although it has been recently speculated that epigenetic dysfunction is also 
likely to be important (Lunnon and Mill, 2013). 
 
Epigenetics refers to the reversible regulation of various genomic functions occurring independently of DNA 
sequence, with cytosine methylation being the best understood and most stable epigenetic modification 
modulating the transcription of mammalian genomes. Recent studies have identified global- and site-specific 
alterations in 5-methylcytosine (5-mC) levels in AD brain (Bakulski, et al., 2012,Lunnon, et al., 
2013,Mastroeni, et al., 2010,Mastroeni, et al., 2009,Rao, et al., 2012). 
 
A number of additional cytosine modifications have recently been described. 5-hydroxymethylcytosine (5-
hmC) has been shown to be enriched in brain (Khare, et al., 2012), suggesting it may play an important role 
in neurobiological phenotypes and disease. Importantly, current approaches based on sodium bisulfite 
converted DNA are unable to distinguish between 5-mC and 5-hmC (Nestor, et al., 2010). 5-hmC is believed 
to be an intermediate step in the demethylation of 5-mC to unmodified cytosine by the oxidation of 5-mC by 
ten eleven translocation (TET) proteins (Tahiliani, et al., 2009). 5-hmC is thought to play a specific role in 
transcriptional regulation as it is recognised by key proteins that do not recognise 5-mC (Jin, et al., 2010), 
has a distinct genomic distribution to 5-mC (being predominantly found in gene promoters and gene bodies 
and rarely in intergenic regions (Jin, et al., 2011,Stroud, et al., 2011)), is more abundant in constitutive exons 
than alternatively spliced ones (Khare, et al., 2012) and has a lower affinity to methyl-binding proteins than 5-
mC (Hashimoto, et al., 2012). 5-hmC appears to be present in all tissues, although at differing levels, with 
the highest levels observed in brain (Li and Liu, 2011) with enrichment in genes involved in synapse-related 
functions (Khare, et al., 2012); in contrast the distribution of 5-mC appears to be relatively uniform across 
tissues (Globisch, et al., 2010). It has been suggested that while some hydroxymethylated-CpG loci are 
stable during aging, others are more dynamically altered (Szulwach, et al., 2011).  
 
In 2011, two additional cytosine modifications were described in mouse embryonic stem cells and somatic 
tissues (Inoue, et al., 2011,Ito, et al., 2011). 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) were 
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found to result from the further oxidation of 5-hmC by TET proteins (Ito, et al., 2011), suggesting that these 
modifications represent further steps along the demethylation pathway (Inoue, et al., 2011). Although little is 
known about their functional role and prevalence in the healthy genome, recent studies have mapped 5-fC to 
gene regulatory elements, namely poised enhancers and CpG island promoters (Raiber, et al., 2012,Song, 
et al., 2013).   
 
The aim of the current study was to investigate the relative abundance of the four described cytosine 
modifications across two distinct anatomical brain regions (entorhinal cortex (EC) and cerebellum (CER)) in 
tissue obtained from AD cases and elderly controls. 
 
2. Methods 
2.1 Subjects and Sample Preparation 
Formalin-fixed tissue punches from the EC and CER were obtained from AD cases (n=13) and cognitively 
normal elderly control (CTL) subjects (n=8) from the MRC London Neurodegenerative Diseases Brain Bank 
(http://www.kcl.ac.uk/iop/depts/cn/research/MRC-London-Neurodegenerative-Diseases-Brain-Bank/MRC-
London-Neurodegenerative-Diseases-Brain-Bank.aspx). Sample demographics are shown in Table S1. 
 
2.2 Immunofluorescence 
Samples were cryosectioned at 10μm on a freezing Cryostat before immunostaining with antibodies 
purchased from Active Motif against 5-mC (Cat# 39649), 5-hmC (Cat# 39791), 5-caC (Cat# 61225) and 5-fC 
(Cat# 61223). Briefly following antigen retrieval (10mM sodium citrate, 0.05% tween, pH6.0, 80°C), 
quenching of endogenous immunofluorescence (300mM glycine) and membrane permeabilisation (Triton-X), 
non-specific binding was blocked with 10% normal goat serum (NGS) (Vector Laboratories) for 30 minutes 
prior to the addition of primary antibody (1:2000 dilution in 5% NGS for 16 hours at 4°C). Slides were 
incubated with biotinylated goat secondary antibody (Vector Laboratories) at 1:200 dilution for 1 hour, 
followed by streptavidin-AF596 (Life Technologies) for 1 hour. To minimise auto-fluorescence samples were 
incubated with 0.3% Sudan Black for 30 minutes then mounted on coverslips with Prolong-Gold with DAPI 
(Life Technologies).  
 
2.3 Microscopy and Analysis 
5 
 
Appropriate controls to demonstrate the specificity of antibodies were included for every sample, including a 
primary antibody control (incubation with the relevant nucleoside (Inoue, et al., 2011) prior to staining) and a 
secondary antibody control (incubation in the absence of primary antibody). Immunofluorescence images 
were acquired on a Zeiss Axio Imager II at 40X magnification, with all camera and microscope settings 
constant for all images taken within each antibody. The two control sections were checked by eye for each 
slide followed by the capture of 10 images from non-overlapping fields of view taken from each of two 
stained sections. Images were analysed using an ImageJ script to determine the level of fluorescence per 
positive cell that applied a threshold pixel value to the red (AF546) channel to create a binary mask image, 
which was then used as a template for measuring the red fluorescence. A binary mask was used as it 
allowed the measurement of fluorescence only within the nuclei and removed any non-specific background 
staining from the analysis. We then calculated the intensity within each nuclei staining positive in a given 
image and generated an average per cell by dividing the total fluorescence intensity in the binary mask of a 
given image by the number of nuclei staining positive in that image. This was then averaged across the 10 
images. Data was assessed for normality and analyzed first using mixed effects modelling in STATA 
(StataCorp) to identify differences between AD cases and controls across each brain region, while controlling 
for age and gender. When an association with disease was observed we employed linear modelling to look 
for differences associated with Braak score, a measure of disease stage (Braak and Braak, 1991) whilst 
controlling for age and gender. 
3. Results and Discussion  
3.1 Each cytosine modification is present in adult human brain 
Initially we sought to investigate whether each of the four cytosine modifications could be detected in adult 
human brain. Because two of the antibodies (5-fC and 5-caC) had yet to be tested in human samples, we 
first stained sections of human EC with antibodies specific to each modification (Fig 1). Staining of all four 
antibodies co-localised with DAPI confirming nuclear staining. To test for non-specific staining, each antibody 
was incubated with its complimentary nucleoside prior to staining to act as a negative control. As expected 
no staining was observed, demonstrating the specificity of the antibodies.  Similarly no staining was 
observed in the absence of the primary antibody. Once we had established the specificity of the antibodies 
and the presence of each cytosine modification in human brain we compared their relative abundance in two 
distinct anatomical brain regions and whether different levels are present in AD cases compared to controls 
(Fig 2).   
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3.2 Cross-tissue differences in 5-mC in AD 
Recent studies have demonstrated differential DNA methylation at specific loci between EC and CER 
(Davies, et al., 2012) and between AD and controls (Lunnon, et al., 2013). Here, we found no significant 
difference in global 5-mC level between brain regions (p=0.286) nor in disease (p=0.401) (Fig 2A). Similarly 
two previous studies have also demonstrated no difference in 5-mC in CER in AD (Mastroeni, et al., 
2010,Mastroeni, et al., 2009), however one of these studies showed decreased 5-mC in AD EC (Mastroeni, 
et al., 2010). Discrepancies between that study and our own could be due to a number of technical issues, 
including different reagents, fewer samples within our study, different sample cohorts and perimortem 
differences such as post-mortem delay (PMD) and brain pH, where their influence on DNA methylation are 
currently unknown (Pidsley and Mill, 2011). 
 
3.3 Cross-tissue differences in 5-hmC in AD 
We found an overall significant effect of disease status (p<0.001) but not brain region (p=0.061) on 5-hmC 
levels, with a significant decrease in 5-hmC in AD compared to control in both EC (p<0.001) and CER 
(p=0.0476) (Fig 2B).  We also observed a significant negative correlation between global 5-hmC and Braak 
score, a measure of AD neuropathology and disease stage, in both the EC (r=0.6927, p<0.001) and CER 
(r=0.2795, p=0.029). Our findings indicate that there is a global reduction in 5-hmC in AD brain that is 
present in both regions of primary neuropathology (EC) and regions largely devoid of neuropathology (CER), 
suggesting a potential global response to the disease process. Our results also concur with a recent study by 
Chouliaras et al that identified AD- and neuropathology-associated reductions in glial 5-hmC in the 
hippocampus and in the affected sib of a monozygotic twin pair discordant for AD (Chouliaras, et al., 2013).  
 
3.4 Cross-tissue differences in 5-fC and 5-caC in AD 
We found an overall significant effect of brain area (p<0.001), but not of disease (p=0.372) on 5-fC 
abundance, with significantly less 5-fC in EC than CER in AD (p=0.0026), and a near-significant reduction in 
controls (p=0.072) (Fig 2C). There was no significant effect of brain area (p=0.810), nor disease (p=0.194) 
on 5-caC levels (Fig 2D).  Both 5-fC and 5-caC are reported to be present at 10-1000 fold lower levels than 
5-hmC in primordial germ cells (Vincent, et al., 2013), accounting for between 3-20 parts per million 
cytosines across the genome (Song, et al., 2012). 
 
Conclusions 
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This study confirmed that four cytosine modifications are present in adult human brain and that there is a 
significant reduction in 5-hmC in AD, across two different anatomical regions of the brain. These data concur 
with previous reports of an AD-associated reduction in 5-hmC in the hippocampus (Chouliaras, et al., 2013). 
Although there was a regional difference in 5-fC levels, no AD-associated changes in 5-mC, 5-fC, or 5-caC 
were observed, although previous reports have shown decrements in 5-mC in AD EC and hippocampus 
(Chouliaras, et al., 2013,Mastroeni, et al., 2010). Given the relatively small numbers of samples assessed in 
this study, further research investigating the specificity of the differences in 5-hmC and 5-fC we report, 
particularly across different neuron and glia subtypes, will be of particular interest to the field.  Our 
observation has implications for current efforts to map site-specific changes in 5-mC in AD using bisulfite-
based approaches that cannot distinguish between 5-mC and 5-hmC and suggests that disease-associated 
differentially methylated regions (DMRs) should be interrogated using approaches that can specifically target 
these modifications (e.g. oxidative-bisulfite sequencing (Booth, et al., 2012,Booth, et al., 2013).  
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Fig 1: Immunofluorescence demonstrating the specificity of the antibodies used in this study. At the 
concentrations used no staining was observed in either the no primary antibody control, or the nucleoside 
control. Staining of tissue (in absence of controls) was co-localised with DAPI, demonstrating nuclear 
staining.  
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Fig 2: Differences in nuclear fluorescence intensity for each cytosine modification in tissue from control 
(black) and AD (white) brains. Data is represented as the mean fluorescence per positive cell across all 
samples in the group (±SEM). (A) There was no difference in 5-mC levels in AD samples, or across brain 
regions.(B) There was an overall effect of disease on 5-hmC levels (p<0.001), with a decrease in 5-hmC in 
AD samples compared to control in both the EC (p<0.001) and CER (p=0.0476) (C) There was a significant 
effect of brain region on 5-fC levels (p<0.001), with a significant difference in 5-fC in EC compared to CER in 
AD (p=0.0026) (C). There was no difference in 5-caC in AD samples, or across brain regions (D). Between 
groups p-values are tabulated (E). 
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Supplementary Material 
 
 
  CTL AD P value 
Gender (F/M) 2/6 7/6   
Age 77.5 (2.25) 78.6 (1.88) 0.705 
Amyloid score 0.63 (0.26) 2.92 (0.08) 3.97x10-9 
Braak score 0.75 (0.25) 5.62 (0.19) 1.55 x10-12 
Brain pH 6.41 (0.12) 6.39 (0.17) 0.911 
PMD 34.1 (7.88) 32.9 (5.46) 0.890 
 
 
Table S1: Sample demographics for CTL subjects (n=8) and AD cases (n=13) used in the study. Two 
measures of neuropathology were used in the cohort. First an amyloid score of a value between 0 and 3 for 
the degree of amyloid pathology within the temporal lobe. Second the Braak score as a measure of stage of 
disease. Both these measures were made by a trained neuropathologist at post-mortem. AD cases had 
significantly higher amyloid (p=3.97 x10
-9
) and Braak (p=1.55 x 10
-15
) scores than control cases. All AD 
cases in the study had detectable amyloid plaques and a minimum Braak stage >5, whilst controls had a 
maximum Braak stage<2. Other post-mortem measures that were collected at autopsy and did not differ 
between the groups, including Brain pH and post-mortem delay (PMD). In subsequent analyses data was 
controlled for the effect of gender, as more males were in the control group, and age, as this is known to 
affect methylation profiles.  
